LitAlert ~~ GeneLit.com

    • Neoadjuvant therapy of BRCA1-driven ovarian cancer by combination of cisplatin, mitomycin C and doxorubicin.
    • Gorodnova TV, Sokolenko AP, Kotiv KB, Sokolova TN, Ivantsov AO, Guseynov KD, Nekrasova EA, Smirnova OA, Berlev IV, Imyanitov EN.
    • Hered Cancer Clin Pract. 2021 Feb 3;19(1):14. doi: 10.1186/s13053-021-00173-2.
    • Satisfaction with prophylactic risk-reducing salpingo-oophorectomy in BRCA mutation carriers is very high and little dependent on the participants' characteristics at surgery: a prospective study.
    • Grandi G, Sammarini M, Cortesi L, Toss A, Botticelli L, Varliero F, Sighinolfi G, Barbieri E, Facchinetti F.
    • Menopause. 2021 Feb 1. doi: 10.1097/GME.0000000000001737. Epub ahead of print.
    • PARPi after PARPi in epithelial ovarian cancer.
    • Essel KG, Behbakht K, Lai T, Hand L, Evans E, Dvorak J, Ding K, Konecny G, Moore KN.
    • Gynecol Oncol Rep. 2021 Jan 11;35:100699. doi: 10.1016/j.gore.2021.100699. eCollection 2021 Feb.